Abstract: Methods and kits for sampling mucous from within a sinus to determine if a single sample includes one or more bacterial types indicating a bacterial infection, such as bacterial sinusitis, and one or more viruses indicating a viral infection, such as influenza.

Abstract: The disclosure concerns a method and a device for enriching cells, cell fragments and molecules from whole blood for a specific detection of at least one population of cells, cell fragments or molecules contained therein. The task was to detect a broad spectrum of target objects including their molecules simply, quickly and yet sensitively and specifically from whole blood. According to the disclosure, not the target objects themselves, but matrix objects are specifically enriched, but target objects are specifically analyzed and thus a specific and sensitive detection of target objects is achieved.

Abstract: A method for determining in a sample, by mass spectrometry, the amount of one or more analytes selected from the group consisting of N-acetylthreonine, TMAP, phenylacetylglutamine, tryptophan, creatinine, meso-erythritol, arabitol, myo-inositol, N-acetyl serine, N-acetylalanine, 3-methylhistidine, trans-4-hydroxyproline, kynurenine, urea, C-glycosyltryptophan, 3-indoxyl sulfate, pseudouridine, and combinations thereof is described. The method comprises subjecting the sample to an ionization source under conditions suitable to produce one or more ions detectable by mass spectrometry from each of the one or more of the analytes; measuring, by mass spectrometry, the amount of the one or more ions from each of the one or more analytes; and using the measured amount of the one or more ions to determine the amount of each of the one or more analytes in the sample. Also described is a kit comprising one or more isotopically labeled analogues as internal standards for each of the one or more analytes.

Abstract: The present disclosure relates generally to conformation-specific antibodies that can bind to and neutralize the activity of phosphorylated-Threonine 231-tau protein (pT231-tau). The antibodies of the present technology are useful in methods for treating a neurological disorder associated with elevated cis-pT231-tau protein expression in a subject in need thereof.

Abstract: Methods for diagnosing a subject as a candidate for removal of a solid tumor without preoperative chemoradiation therapy, and methods for treating patients having solid tumors, who have one or more of genomic instability, elevated double stranded DNA breaks, elevated gamma-H2AX foci, or elevated replication stress and/or double stranded break-signalling (DSB-signalling) biomarkers in peripheral blood lymphocytes (PBLs) are provided herein.

Abstract: The invention provides gastroenterological cancer determination methods that involve contacting a specimen, an antibody 1 that recognizes an ? chain of human haptoglobin, and an antibody 2 that recognizes a ? chain of human haptoglobin and does not recognize human haptoglobin in which an S—S bond is cleaved to form a complex 1, or contacting the specimen and two antibodies selected from the antibodies 2 that recognize a ? chain of human haptoglobin and do not recognize human haptoglobin in which an S—S bond is cleaved to form a complex 2. A determination is made based on the measurement of complex 1 or 2. Alternatively, the specimen and two antibodies selected from the antibodies 1 that recognize an ? chain of human haptoglobin are contacted to form a complex 3, and a determination is made by comparing the measurement results of complex 1 or 2 with complex 3.

Abstract: Methods and systems directed to monitoring for the presence or progression of amyloid diseases via detection of amyloid fibrils in a sample from an individual are disclosed. An individual, or sample from an individual, is treated with a reagent including a fluorescent protein. The fluorescent protein in the reagent binds to amyloid fibrils present in the sample. Detecting a signal from fluorescent protein bound to the treated sample indicates the presence of amyloid fibrils in the sample and possible diagnosis of an amyloid disease. The presence and progression of an amyloid disease is monitored by quantifying signal intensity from samples taken over time. Treatment with a reagent including a fluorescent protein inhibits amyloid fibril formation by providing the reagent to an environment including amyloid monomers. The fluorescent protein binds to amyloid oligomers during the lag phase and/or elongation phase of amyloid fibril formation, preventing formation of mature amyloid fibrils.

Abstract: Certain aspects of the present disclosure generally relate to systems and methods for determining viruses such as coronaviruses. For instance, some aspects are directed to systems and methods for determining viruses using a partitioning system. Within the partitioning system, free RNA or other nucleic acids may preferentially partition into one phase, while intact viruses may be present in the other phase or in both phases. Accordingly, in some cases, free RNA or other nucleic acids may be preferentially removed, e.g., as compared to intact RNA or other nucleic acids present within a virus. In some cases, the phase containing intact viruses can be determined to determine the infectiousness, e.g., of a sample arising from a subject. This may be useful, for example, for distinguishing subjects who are capable of spreading an infection from those who are not infectious.

Abstract: The present invention provides methods for analysing a urine sample from a subject comprising exposing the urine sample to a lysis buffer which is capable of releasing at least one biomarker from cells in the urine sample. The present invention further provides kits, devices, and apparatuses that can be used in these methods. Finally, the present invention provides methods for detecting the presence of a urological cancer in a subject comprising performing an assay on a sample from a subject to determine the concentration of an Mcm protein.

Abstract: A method for finding manufactured or to-be-manufactured products for defects includes obtaining basic information on processing history of products passed by each manufacturing machine at each processing workstation, and obtaining processing factor information of same, where each product is passed by a defect detection workstation after the product is passed by at least one processing workstation. The method includes obtaining quality information detected by each defect detection workstation. The method determines one or more problem manufacturing machines at one or more problem processing workstations according to the basic information on processing history and the quality information of the products. The method further determines one or more processing factors which influence the problem manufacturing machines according to the processing factor information of each manufacturing machine and the quality information of the products.

Abstract: Systems and methods are provided for improving skincare product formulations to address predicted skin trends. A biomarker analysis system is used to determine concentrations of various protein biomarkers of a user. A skin diagnosis computing device uses the protein biomarker concentrations to determine one or more skin trends, and determines one or more skincare product ingredients to address the skin trends. A skincare product is compounded that includes the one or more skincare product ingredients.

Abstract: Provided is a method for evaluating the progression of glioma in an individual comprising monitoring the levels of circulating exosomes that are positive for survivin and a glial marker (such as glial fibrillary acidic protein). An increase in the level of such exosomes is indicative of poor prognosis. Levels of circulating exosomes that are positive for survivin and glial marker can also be used for evaluating the efficacy of a therapy for glioma in an individual, and modifying the therapy or introducing additional therapy if levels of such exosomes are found to be increasing.

Abstract: Magnetic beads having cell components of interest are translated between a sequence of processing wells in a tray without need for pipetting. The circular tray contains one or more sequences of wells each interconnected by a respective channel. The tray is rotated about a central axis and a magnet, an agitator, and a heater provided external to the tray enable magnetic bead translation, mixing, and incubation, respectively. The magnet proximate a well forms a cluster of beads. Manipulation of the tray in rotation and elevation results in translation of the cluster from one well, through a channel, and into an adjacent well. The well containing a cluster may be rotationally positioned in front of the agitator, the agitator extended into contact with the well, followed by mechanical agitation. The heater, disposed beneath the tray, may accept a well lowered thereto for selective heating.

Abstract: The present invention provides human bone-marrow cells enriched with functional mitochondria, methods for their production, and therapeutic methods utilizing such cells.

Abstract: The invention relates to the field of medical diagnostics. Provided are methods and kits for determining the health status of a subject, for early detection of tissue damage, for early diagnosis and monitoring of a disease, and/or for evaluation of treatment effectiveness in a subject using circulating tissue macrophages (CTM) as a mirror of disrupted tissue homeostasis and disease.

Abstract: Various systems and methods for predicting metabolic and bariatric surgery outcomes are provided. The systems and methods can also provide predictions for non-surgical metabolic and bariatric treatments. In general, a user can receive predictive outcomes of multiple bariatric procedures that could be performed on a patient. In one embodiment, a user can electronically access a metabolic and bariatric surgery outcome prediction system, e.g., using one or more web pages. The system can provide predictive outcomes of one or more different bariatric surgeries for the patient based on data gathered from the user and on historical data regarding outcomes of the different bariatric surgeries. The system can additionally provide predictive outcomes for not having any treatment and/or a comparison of the predictive outcomes of the one or more different bariatric surgeries to the predictive outcomes for not having any treatment.

Abstract: A marker having excellent sensitivity and specificity to pancreatic cancer and intraductal papillary mucinous neoplasms. Also, a kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms to detect the marker, and a method for evaluating a metastasis of a pancreas cancer cell by using the marker. The marker for pancreatic cancer and intraductal papillary mucinous neoplasms according to the present invention comprises one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein. The kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms according comprises an antibody to one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein.

Abstract: The described invention provides an ex vivo dynamic multiple myeloma cancer niche contained in a pumpless perfusion culture device. The dynamic multiple myeloma cancer niche includes (a) a three-dimensional tissue construct containing a dynamic ex vivo bone marrow niche, which contains a mineralized bone-like tissue containing viable osteoblasts self-organized into cohesive multiple cell layers and an extracellular matrix secreted by the viable adherent osteoblasts; and a microenvironment dynamically perfused by nutrients and dissolved gas molecules; and (b) human myeloma cells seeded from a biospecimen composition comprising mononuclear cells and the multiple myeloma cells. The human myeloma cells are in contact with osteoblasts of the bone marrow niche, and the viability of the human myeloma cells is maintained by the multiple myeloma cancer niche.

Abstract: Devices that include a low sensitivity bulk acoustic wave (BAW) resonator sensor including a surface to which a low recognition component is immobilized, the low recognition component being configured to selectively bind the analyte, an analyte molecule to which a tag is linked, or a tag, or any one of these molecules to which an amplification element-linked second recognition component is bound; a high sensitivity BAW resonator sensor including a surface to which a high recognition component is immobilized, the high recognition component being configured to selectively bind the analyte, an analyte molecule to which a tag is linked, or a tag, or any one of these molecules to which an amplification element-linked second recognition component is bound; one or more containers housing an amplification molecule, the amplification element-linked second recognition component, and optionally one or both of the tag and the analyte molecule.

Abstract: A fluid detection system includes a wicking material to draw fluid away from a first location with space limitations and proximate to a fluid device or a fluid interface. The wicking material draws the fluid to a remote fluid indicator at a second location. Contact between fluid and the remote fluid indicator produces a detectable alteration to the remote fluid indicator, and a non-contact optical sensor detects the alteration.

Abstract: A method for exchange imaging of at least two targets in a sample includes (a) incubating a sample with at least two or more target-recognizing antibodies, each bound to a corresponding monovalent tight antibody binder-docketing moiety (MTAB-DM) reagent capable of binding monovalently to the target-recognizing antibodies, (b) applying at least two imager moieties corresponding to the MTAB-DM, either in series, in batches, or in parallel, and (d) imaging the at least two imager moieties either in series, in batches, or in parallel.

Abstract: The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus.

Abstract: The present invention relates to methods and compositions for quantifying hemoglobin using, inter alia, a peroxidase substrate and hydrogen peroxide.

Abstract: Disclosed herein are caged haptens and caged hapten-antibody conjugates useful for enabling the detection of targets located proximally to each other in a sample.

Abstract: Hydrophilic, high quantum yield, chemiluminescent acridinium compounds with increased light output, improved stability, fast light emission and decreased non specific binding are disclosed. The chemiluminescent acridinium esters possess hydrophilic, branched, electron-donating functional groups at the C2 and/or C7 positions of the acridinium nucleus.

Abstract: Disclosed herein are methods, kits, tests, and systems for detecting, predicting, monitoring, or ruling out preeclampsia in pregnant women. Also provided herein are novel diagnostic markers, methods of data analysis, assay formats, and kits employing such markers to improve one or more characteristics of a test for identifying or ruling out preeclampsia based on biomarkers from patient samples.

Abstract: A device and method for use in capturing a substance in a liquid, by feeding the liquid through a capturing device including: a lateral capillary flow matrix and a capturing matrix in fluid communication with the lateral capillary flow matrix so as to produce two lateral flows sufficient to impart transverse oscillations to the lateral flow in the capturing matrix, such oscillations driving the liquid into the interior of the capturing matrix thereby exposing its interior to the liquid.

Abstract: The present invention relates to a method of dewatering post fermentation fluids in a starch to ethanol process. More particularly the invention relates to use of a nuclease enzyme for separation of whole stillage into an insoluble fraction and a supernatant fraction. In a specific embodiment the present invention relates to a method of dewatering whole stillage comprising the steps of: i) subjecting whole stillage to one or more nuclease enzymes; ii) separating the material into an insoluble fraction and a supernatant fraction.

Abstract: Disclosed herein are system, method, and computer program product embodiments for performing a database migration with automatic privilege retention and restoration. Embodiments provide for migrating a source database object at a source database to a target database object at a target database. The embodiments provide for binding a retention tag to database objects in order to mark the objects whose privileges are to be retained during a database migration. This approach enables privileges of database objects that are involved in a database migration to be automatically restored at target database objects after the migration.

Abstract: The present invention relates to cell-based methods for screening body fluids or tissues for factors that prevent cellular uptake of lysosomal enzymes, including neutralizing factors such as neutralizing antibodies, that arise as a result of lysosomal enzyme replacement therapy.

Abstract: The present invention concerns a method for the in vitro detection of an increased risk of diabetic nephropathy in a subject suffering from diabetes and being normoalbuminuric. Another aspect of the invention pertains to a method for the in vitro identification of a marker for prediction of diabetic nephropathy. Finally, the invention concerns a kit comprising means for detecting at least two proteins selected from the group consisting of heparan sulfate proteoglycan core protein or fragments thereof, carbonic anhydrase 1, prothrombin or fragments thereof, tetranectin, CD59 glycoprotein, plasma serine protease inhibitor, mannan-binding lectin serine protease 2 or isoforms thereof, antithrombin-III, alpha-1-antitrypsin, collagen alpha-1(I) chain, alpha-enolase, histone H2B type 1-O, glutaminyl-peptide cyclotransferase, protein AMBP and zinc-alpha-2-glycoprotein.

Abstract: The present disclosure relates to methods of characterizing disease. In particular, this invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects suffering from sepsis, based on the characterization of genes associated with a reactive oxygen species (ROS) molecular signature.

Abstract: The present disclosure provides methods and systems directed to cell-free identification and/or monitoring of pregnancy-related states. A method for identifying or monitoring a presence or susceptibility of a pregnancy-related state of a subject may comprise assaying a cell-free biological sample derived from said subject to detect a set of biomarkers, and analyzing the set of biomarkers with a trained algorithm to determine the presence or susceptibility of the pregnancy-related state.

Abstract: The invention relates to a device for determining a cellular-bound analyte in a liquid sample, comprising a separation matrix with at least one indicator zone. The invention is characterized in that the indicator zone comprises a first antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody. The separation matrix is preferably designed in the form of the membrane of a lateral flow assay device or as a gel matrix. In a particularly preferable manner, the device comprises a membrane (2) with a charging zone (5) for applying the liquid sample, at least one indicator zone which can interact with the cellular-bound analyte, and at least one absorption region (3) which absorbs the liquid after passing the indicator zone. The indicator zone lies between the charging zone (5) and the absorption region (3).

Abstract: A single-channel, chemical-immunological hybrid biosensor is disclosed. According to an embodiment, the hybrid biosensor includes a reaction strip 100 in the form of a porous membrane through which a sample 1 moves by capillary action. the reaction strip 100 is in the form of a porous membrane through which the sample 1 moves by capillary action. Biomarkers in the sample 1 are independently detected based on a chemical reaction and binding reactions on the reaction strip 100.

Abstract: Disclosed is a method for measuring phosphorylated tau protein in a biological sample collected from a subject, comprising the steps of: preparing a measurement sample containing a non-capture bead and a capture bead to which an immune complex is bound, by forming the immune complex of the phosphorylated tau protein in the biological sample, a capture antibody and a detection antibody on the capture bead, in the presence of the non-capture bead; and detecting a signal derived from the immune complex in the measurement sample.

Abstract: A test tube including an annular body having an open proximal end and a closed distal end, and an longitudinal member in a distal portion of an interior of the annular body, the longitudinal member is substantially parallel to a central longitudinal axis of the annular body and is connected to an internal surface of the distal portion of the annular body.

Abstract: Contact of endothelial cells with inhibitors of inhibin and/or the alpha subunit of inhibin can be utilized to modify the activity of endothelial cell expression products including SMAD 1/5. Methods can also include inhibiting Alk1 and/or endoglin as components of inhibin-activated pathway of SMAD 1/5 signaling. Methods can be combined with other anti-angiogenesis therapies such as anti-VEGF therapies. Methods can be utilized in treatment of inhibin-expressing cancers (e.g., ovarian cancer, pancreatic cancer) as well as other pathologies such as preeclampsia and PCOS.

Abstract: The present disclosure provides a paper-based vertical flow test platform including: a detection portion; a movable conjugation portion having an enzyme-labelled protein; and an absorbent portion. The present disclosure further provides a detection method by using the same. With the folding and sliding design, the present disclosure can reduce the volume of specimen fluids used, and prevent the interference problem. Also, a portable diagnostic test platform is provided with ease of use, lower cost, higher sensitivity and longer storage period to meet requirements of point-of-care for the fast, simple and stable detection.

Abstract: A reagent for enhancing a chemiluminescent reaction includes luminol or luminol derivatives, an oxidant, an electron mediator, and an enhancer. The enhancer is a nitrogen-containing fused heterocyclic compound having at least two nitrogen atoms. The present disclosure further provides a kit for enhancing a chemiluminescent reaction comprising the foregoing reagent.

Abstract: A method is provided for determining the presence of soluble, misfolded ?-synuclein protein in a biological sample. The method comprises contacting the biological sample with a pre-incubation mixture, the pre-incubation mixture comprising: a monomeric ?-synuclein protein; a buffer composition; a salt; and an indicator, to form an incubation mixture. An incubation cycle is conducted on the incubation mixture in the presence of either a silicon nitride bead or a borosilicate glass bead having a diameter of from about 1 mm to about 5 mm. The method further comprises determining if a detectable amount of misfolded ?-synuclein aggregate is present in the biological sample.

Abstract: Provided is a color encoding method including providing a composition including a liquid medium and magnetic nanoparticles dispersed in the liquid medium; applying a magnetic field to the composition to align the magnetic nanoparticles; and applying a patterned energy source to the composition to solidify the composition, wherein more than one region of the composition are sequentially solidified with varying magnetic field strength to fix a plurality of color codes.

Abstract: This disclosure provides antigen compositions useful for diagnosing Lyme disease and for detecting antibodies that bind to Borrelia antigens. The antigenic compositions comprise a mixture of hybrid peptides and Borrelia proteins. This disclosure also provides devices, methods, and kits that are useful for diagnosing Lyme disease and for detecting anti-Borrelia antibodies in a sample to aid in the diagnosis of Lyme disease.

Abstract: Disclosed herein are caged haptens and caged hapten-antibody conjugates useful for enabling the detection of targets located proximally to each other in a sample.

Abstract: Materials and methods for detecting and treating Coccidioidomycosis (Valley Fever) are provided herein. For example, materials and methods for enriching and detecting biomarker antigens (e.g., polypeptides and/or glycans) from Coccidioides immitis and Coccidioides posadasii, the fungi that cause Valley Fever, are described herein, as are methods for treating an individual for Valley Fever based on the results of the described detection methods.

Abstract: Provided herein are chimeric polypeptides that may be used, e.g., for the diagnosis of or vaccination against Ehrlichia chaffeensis and/or Ehrlichia canis.

Abstract: A method for diagnosis of IgA nephropathy is provided using a combination of alpha-1B-glycoprotein (A1BG) or a truncated fragment thereof having a molecular weight of 13-60 kDa, orosomucoid 1 (ORMI), and Ig lambda-2 chain C regions (IGLC2) as protein markers in a urine sample from a subject.

Abstract: Disclosed herein are conjugates comprising a biomolecule linked to a label that have biological activity and are useful in a wide variety of biological applications. For example, provided herein are polymerase-nanoparticle conjugates including a polymerase linked to a nanoparticle, wherein the conjugate has polymerase activity. Such conjugates can exhibit reduced aggregation and improved stochiometries wherein the average biomolecule:nanoparticle ratio approaches or equals 1:1. Also disclosed herein are improved methods for preparing such conjugates, and methods and systems for using such conjugates in biological applications such as nucleotide incorporation, primer extension and single molecule sequencing.

Abstract: Provided herein is a recombinant viral vector having packaged therein an expression cassette comprising an engineered complement regulator factor H (fH), wherein the gene encodes a hfH protein variant comprising short consensus repeats (SCRs) 1-4, 6-8, and 17-20. Pharmaceutical compositions containing this vector and plasmids comprising nucleic acid sequences that encode the fH protein variant are also provided.

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.